Interestingly, EGFR-TKI plus bevacizumab treatment in patients with EGFR-mutated advanced NSCLC and BIM deletion polymorphisms resulted in a significantly higher ORR (94.4% vs. 40%; p > 0.001), longer PFS (11.12 months vs. 7.87 months; p = 0.001), and prolonged OS (30.9 months vs. 25.4 months; p = 0.06) compared to those of patients receiving EGFR-TKI treatment alone (Table 5) [77]. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.